Author Archives: Jan Paschal

BBB Foods, Inc. (TBBB proposed), the parent of Mexico’s discount grocery store chain, increased its IPO’s size early today to $572.2 million by raising both the number of shares and the price range – hours ahead of the IPO’s pricing, expected tonight after the market’s close. The IPO’s size was raised to 33.66 million shares […]

Clinical biotech Kyverna Therapeutics (KYTX) priced its upsized IPO at $22.00 – $1.00 above its recently increased range – on 14.5 million shares – the number of shares in the prospectus – to raise $319 million on Wednesday night (Feb. 7, 2024). The $22.00 IPO price exceeded Kyverna’s price range of $20.00 to $21.00, which was disclosed on Tuesday […]

Kyverna Therapeutics (KYTX Proposed) increased its IPO’s size by 48.5 percent early today – Tuesday, Feb. 6, 2024 – by raising both the number of shares and the price range, according to an S-1/A filing. The new terms: 14.5 million shares – up from 11.12 million originally – at $20.00 to $21.00 – up from […]

It’s all in the genes. Metagenomi, Inc. (MGX Proposed), a preclinical gene editing company backed by COVID-19 vaccine maker Moderna, disclosed terms for its IPO early today (Monday, Feb. 5, 2024) and launched the deal to price on Thursday night, Feb. 8, 2024. The stock is expected to trade Friday, Feb. 9, on the NASDAQ. J.P. […]

Mexico’s hard discount grocery store chain BBB Foods Inc. (TBBB Proposed) set terms for its IPO today and launched the deal for pricing next week. BBB Foods’ no-frills grocery stores are in the same category as Germany’s Aldi and Lidl chains. The Mexico City-based discount grocery chain plans to offer 28.05 million Class A ordinary […]

Fractyl Health (GUTS) priced its IPO at the $15.00 mid-point of its $14.00-to-$16.00 range – and kept the deal’s size at the 7.33 million shares  in the prospectus – to raise $109.95 million on Thursday night, Feb. 1, 2024. The metabolic therapeutics company is targeting obesity and Type 2 diabetes. The stock dropped below its […]

Alto Neuroscience (ANRO) priced its upsized IPO at $16.00 – the high end of its $14.00-to-$16.00 range. The company increased the deal’s size to 8.04 million shares – up from 6.7 million shares in the prospectus – and raised $128.64 million on Thursday night, Feb. 1, 2024. The Phase 2 clinical biotech is developing drugs […]

Amer Sports (AS) priced its IPO at $13.00 – $3.00 below its $16.00-to-$18.00 range – and increased the deal’s size to 105.0 million shares – up from 100.0 million in the prospectus. The IPO raised $1.37 billion ($1,365.0 million) on Wednesday night, Jan. 31, 2024. Amer Sports is the parent of three big iconic brands, including […]

Two biotechs – Alto Neuroscience and Fractyl Health – pumped some warm air into the chilly February IPO Calendar early today. Both companies disclosed IPO terms in S-1/A filings early Monday morning, Jan.  29, 2024. Both IPOs are set for pricing Thursday night, Feb. 1, 2024, to trade Friday, Feb. 2, 2024: Alto Neuroscience (ANRO […]

More stock at the mid-point: That’s how lung cancer biotech ArriVent BioPharma (AVBP) played it when pricing its IPO on Thursday night (Jan 25, 2024). ArriVent BioPharma increased the IPO’s size to 9.72 million shares – up from 8.33 million shares in the prospectus – and priced the deal at $18.00 – the mid-point of […]